Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Germing

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Leukemia|January 23, 2013
Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblastsB H Yip, C Vuppusetty, M Attwood, et al.
Leukemia|January 15, 2013
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantationT Schroeder, A Czibere, U Platzbecker, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Leukemia|November 26, 2015
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemiaS Geyh, M Rodríguez-Paredes, P Jäger, et al.
Annals of Hematology|November 19, 2013
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosisSigrid Machherndl-Spandl, W Sega, H Bösmüller, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyU Platzbecker, F Braulke, A Kündgen, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Leukemia|August 26, 2006
The JAK2 V617F mutation is rare in RARS but common in RARS-TM M Ceesay, N C Lea, W Ingram, et al.
Leukemia|January 23, 2013
Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblastsB H Yip, C Vuppusetty, M Attwood, et al.
Leukemia|January 15, 2013
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantationT Schroeder, A Czibere, U Platzbecker, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Leukemia|November 26, 2015
Functional inhibition of mesenchymal stromal cells in acute myeloid leukemiaS Geyh, M Rodríguez-Paredes, P Jäger, et al.
Annals of Hematology|November 19, 2013
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosisSigrid Machherndl-Spandl, W Sega, H Bösmüller, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyU Platzbecker, F Braulke, A Kündgen, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Pageof 13